Hennion & Walsh Asset Management Inc. Acquires 14,426 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Hennion & Walsh Asset Management Inc. boosted its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 48.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,166 shares of the company's stock after acquiring an additional 14,426 shares during the period. Hennion & Walsh Asset Management Inc.'s holdings in Apellis Pharmaceuticals were worth $966,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Teacher Retirement System of Texas grew its holdings in shares of Apellis Pharmaceuticals by 9.4% during the fourth quarter. Teacher Retirement System of Texas now owns 21,649 shares of the company's stock valued at $691,000 after purchasing an additional 1,864 shares during the last quarter. Entropy Technologies LP acquired a new stake in Apellis Pharmaceuticals during the fourth quarter valued at approximately $445,000. Ameriprise Financial Inc. grew its holdings in shares of Apellis Pharmaceuticals by 2.6% in the 4th quarter. Ameriprise Financial Inc. now owns 882,801 shares of the company's stock worth $28,170,000 after acquiring an additional 22,507 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Apellis Pharmaceuticals by 11.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 212,887 shares of the company's stock worth $6,793,000 after buying an additional 21,822 shares during the period. Finally, Nuveen Asset Management LLC raised its holdings in shares of Apellis Pharmaceuticals by 44.1% during the fourth quarter. Nuveen Asset Management LLC now owns 491,107 shares of the company's stock valued at $15,671,000 after acquiring an additional 150,384 shares during the period. 96.29% of the stock is owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Trading Up 1.0%

APLS traded up $0.19 during trading on Tuesday, reaching $19.58. 1,720,668 shares of the company's stock were exchanged, compared to its average volume of 2,322,427. The company's fifty day moving average price is $18.34 and its 200-day moving average price is $25.49. The firm has a market capitalization of $2.46 billion, a PE ratio of -9.65 and a beta of 0.68. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $16.10 and a fifty-two week high of $43.76. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The company had revenue of $149.90 million during the quarter, compared to the consensus estimate of $197.61 million. During the same quarter in the prior year, the company posted ($0.54) EPS. The company's revenue for the quarter was down 3.2% compared to the same quarter last year. As a group, equities analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analyst Ratings Changes

APLS has been the subject of a number of research analyst reports. Bank of America lowered shares of Apellis Pharmaceuticals from a "buy" rating to a "neutral" rating and reduced their price target for the stock from $41.00 to $23.00 in a research report on Friday, May 9th. Citigroup dropped their target price on shares of Apellis Pharmaceuticals from $49.00 to $41.00 and set a "buy" rating on the stock in a report on Thursday, May 22nd. JPMorgan Chase & Co. raised their price objective on shares of Apellis Pharmaceuticals from $50.00 to $54.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 4th. Wells Fargo & Company upped their target price on Apellis Pharmaceuticals from $26.00 to $29.00 and gave the company an "equal weight" rating in a research note on Monday, June 2nd. Finally, Royal Bank of Canada cut their price target on shares of Apellis Pharmaceuticals from $21.00 to $18.00 and set a "sector perform" rating for the company in a research note on Thursday, May 8th. Nine equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $40.05.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).